Please login to the form below

Not currently logged in
Email:
Password:

Bristol-Myers Squibb names new CEO

Lamberto Andreotti will take over from James Cornelius as CEO at Bristol-Myers Squibb, with Cornelius staying on as chairman  

Bristol-Myers Squibb (BMS) has announced that Lamberto Andreotti, 59, will become the company's chief executive officer on May 4, when James M Cornelius, 66, current chairman and CEO, retires. At the request of the board, Cornelius will remain as chairman. 

"Jim successfully led our transformation into a next-generation biopharma leader with his strategic leadership and consistent focus on delivering our commitments. I am personally grateful for this opportunity to lead Bristol-Myers Squibb in the next phase of our biopharma journey," said Lamberto Andreotti, who is currently president, chief operating officer and a member of the board.  

Lamberto has the full support of Cornelius, who said: "Lamberto has demonstrated extraordinary leadership as president and chief operating officer and I believe he is the natural candidate to replace me as CEO. I have a high level of confidence in Lamberto and that is shared by everyone who has seen him consistently and successfully drive performance."  

Andreotti has been president and chief operating officer since March 2009, responsible for the global pharmaceutical business. He has been with BMS for 12 years in senior international roles. Prior to this he held senior roles at KABI Pharmacia and Pharmacia & Upjohn. 

3rd March 2010

Share

Subscribe to our email news alerts

PMHub

Add my company
SEVEN STONES COLLECTIVE

Hello. We are the Total Health creative agency. It’s our collective mix of talent that gets us to truly different...

Latest intelligence

New Playbook Alert: Virtual Patient Engagement
...
Millennials: the wellness generation
Looking at the results from a global healthcare research study focusing on the patients of the future...
The problem with clinical trials (and how virtual insight-gathering can help)
While still the gold standard of research, clinical trials are often riddled with issues that limit their applicability to broader populations or delay market access....